The primary objective of this study was to evaluate the antihypertensive effect of amiloride added to triple antihypertensive treatment in patients with resistant hypertension and type 2 diabetes mellitus in an open-labelled, non- controlled and non-randomized interventional study.~The secondary objectives were to evaluate the additional effects of amiloride on:~Urinary albumin excretion~Blood pressure control, how many patients reached blood pressure control when amiloride was added to previous triple antihypertensive treatment.~Plasminogen and plasmin excretion (ENaC activity) in the micro-and macroalbuminuric patients in the cohort.~Urokinase plasminogen activator (uPA) activity
To evaluate the antihypertensive effect of amiloride added to triple antihypertensive therapy in patients with resistant hypertension (RH) and type 2 diabetes mellitus (T2DM)